Abbott receives FDA clearance for FreeStyle Libre 3
By HME News Staff
Updated 9:22 AM CDT, Wed June 1, 2022
ABBOTT PARK, Ill. – Abbott has received clearance from the U.S. Food and Drug Administration for its FreeStyle Libre 3 system for people with diabetes age four and up. "The FreeStyle Libre 3 system is a direct result of listening to our customers – and giving them the innovation and sensing technology they've been looking for," said Jared Watkin, senior vice president of Abbott's diabetes care business. "It's a game changer for the millions of people living with diabetes. They'll be able to manage their health minute-by-minute with the world's smallest and thinnest sensor and most accurate 14-day continuous glucose monitoring system." The FreeStyle Libre 3 offers: high accuracy with a 7.9% overall mean absolute relative difference; a small size comparable to two stacked pennies; and Bluetooth integration. It will be available later this year.
Comments